Amarin (AMRN) Issused Patent 8,324,195 for Vascepa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin (AMRN) Still Risky into NCE Amid Vascepa Sales Staff Additions, Financing - Analyst
December 7, 2012 7:20 AM ESTAmarin (Nasdaq: AMRN) is in the dumps Friday morning following a news release Thursday night that it was entering a non-equity financing agreement for $100 million and hiring about 250 to 300 reps for its Vascepa launch.
Today, Wedbush is out with some comments on the news today.
Wedbush said the timing of the release was a surprise following... More
